Outcome of cell suspension allografts in a patient with Huntington's disease.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620884
Title:
Outcome of cell suspension allografts in a patient with Huntington's disease.
Authors:
Maxan, A. [et al]; Harrower, Tim
Abstract:
For patients with incurable neurodegenerative disorders such as Huntington's (HD) and Parkinson's disease, cell transplantation has been explored as a potential treatment option. Here we present the first clinico-pathological study of a patient with HD in receipt of cell-suspension striatal allografts who took part in the NEST-UK multi-centre clinical transplantation trial. Using various immunohistochemical techniques, we found a discrepancy in the survival of grafted projection neurons with respect to grafted interneurons as well as a major ongoing inflammatory and immune responses to the grafted tissue with evidence of mutant huntingtin aggregates within the transplant area. Our results indicate that grafts can survive more than a decade post-transplantation but show compromised survival with inflammation and mutant protein being seen within the transplant site. This article is protected by copyright. All rights reserved.
Citation:
Outcome of cell suspension allografts in a patient with Huntington's disease. 2018 Ann. Neurol.
Publisher:
Wiley
Journal:
Annals of neurology
Issue Date:
4-Oct-2018
URI:
http://hdl.handle.net/11287/620884
DOI:
10.1002/ana.25354
PubMed ID:
30286516
Additional Links:
https://doi.org/10.1002/ana.25354
Type:
Journal Article
Language:
en
ISSN:
1531-8249
Appears in Collections:
Neurology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMaxan, A. [et al]en
dc.contributor.authorHarrower, Timen
dc.date.accessioned2018-10-11T12:33:57Z-
dc.date.available2018-10-11T12:33:57Z-
dc.date.issued2018-10-04-
dc.identifier.citationOutcome of cell suspension allografts in a patient with Huntington's disease. 2018 Ann. Neurol.en
dc.identifier.issn1531-8249-
dc.identifier.pmid30286516-
dc.identifier.doi10.1002/ana.25354-
dc.identifier.urihttp://hdl.handle.net/11287/620884-
dc.description.abstractFor patients with incurable neurodegenerative disorders such as Huntington's (HD) and Parkinson's disease, cell transplantation has been explored as a potential treatment option. Here we present the first clinico-pathological study of a patient with HD in receipt of cell-suspension striatal allografts who took part in the NEST-UK multi-centre clinical transplantation trial. Using various immunohistochemical techniques, we found a discrepancy in the survival of grafted projection neurons with respect to grafted interneurons as well as a major ongoing inflammatory and immune responses to the grafted tissue with evidence of mutant huntingtin aggregates within the transplant area. Our results indicate that grafts can survive more than a decade post-transplantation but show compromised survival with inflammation and mutant protein being seen within the transplant site. This article is protected by copyright. All rights reserved.en
dc.language.isoenen
dc.publisherWileyen
dc.relation.urlhttps://doi.org/10.1002/ana.25354en
dc.rightsArchived with thanks to Annals of neurologyen
dc.subjectWessex Classification Subject Headings::Neurologyen
dc.titleOutcome of cell suspension allografts in a patient with Huntington's disease.en
dc.typeJournal Articleen
dc.identifier.journalAnnals of neurologyen
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.